AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) recently announced a significant milestone with the granting of a new U.S. patent, No. 12312376, titled “Therapeutic Double Stranded RNA and Methods for Producing the Same,” which is set to expire on January 25, 2041. This patent enhances AIM’s intellectual property portfolio by covering manufacturing methods for various therapeutic double-stranded RNA (dsRNA) products, including its lead drug, Ampligen. The new patent synergizes with existing compositions and methods patents, robustly securing AIM’s production capabilities, which is crucial as the company pursues FDA approval across multiple indications.
Ampligen has showcased a wide spectrum of activity in clinical trials targeting significant health issues such as major cancers, viral diseases, and immune system disorders. With this patent, AIM can confidently progress its drug development initiatives, having extended its operational runway until 2041. AIM’s overall patent protection encompasses not only the manufacturing process but also specific therapeutic uses of Ampligen, including treatments for cancer, Post-COVID fatigue, and endometriosis, among others.
AIM CEO Thomas K. Equels emphasized the importance of this patent as a culmination of years spent fortifying the company's international patent landscape. The encompassing protections position AIM to exploit market exclusivity better, supported by multiple Orphan Drug Designations (ODD) from the FDA and the European Medicines Agency (EMA) which facilitate long-term market advantages post-approval.
Despite this positive development, AIM acknowledges the inherent risks and uncertainties surrounding the pharmaceutical landscape, cautioning stakeholders about the unpredictability of FDA approvals and market dynamics. Investors are encouraged to review the associated risks in AIM's filings with the U.S. Securities and Exchange Commission.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) recently received significant validation in the form of a U.S. patent covering the manufacturing methods for its leading therapeutic product, Ampligen. This patent, which extends protection until January 2041, further solidifies AIM's intellectual property portfolio, enhancing its position in the competitive field of immunotherapy.
The strategic granting of this patent comes at a crucial time as AIM seeks FDA approval across various indications, leveraging Ampligen's demonstrated efficacy in treating cancers, viral diseases, and immune disorders. The extended patent coverage not only protects AIM's manufacturing processes but also positions the company favorably for future financial performance. The inclusion of multiple orphan drug designations boosts market exclusivity for Ampligen and potentially allows for faster revenue generation following approval.
Investors should view this development positively. The solid foundation established through AIM’s patent protection offers a could bolster confidence in future trials, particularly as the market continues to gravitate towards novel therapies in oncology and infectious diseases. Moreover, the current portfolio of patents underscores a robust competitive advantage as rivals in the sector strive to develop similar therapies.
However, potential investors must remain cautious. While the patent strengthens AIM's strategic positioning, the ultimate success of Ampligen depends heavily on clinical trial outcomes and subsequent regulatory approvals, both of which carry inherent risks. The market's response to these factors will likely be critical in determining AIM’s stock trajectory over time.
Investors should conduct thorough due diligence and consider market sentiment, regulatory timelines, and the broader competitive landscape when assessing AIM ImmunoTech's stock as a potential investment opportunity. Overall, with solid patent support and a strategic pathway to market, AIM appears to be well-positioned for future growth, contingent on clinical and regulatory successes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Patent portfolio now includes protection for manufacture, methods and compositions
Provides AIM with patent protection for manufacturing Ampligen until 2041
OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No. 12312376, titled “ Therapeutic Double Stranded RNA and Methods for Producing the Same.” The patent expires January 25, 2041.
The new patent covers methods involving the manufacture of a range of therapeutic double-stranded RNA (dsRNA) products, of which Ampligen is included. Combined with AIM’s multiple compositions and methods patents involving Ampligen, this manufacturing patent, along with AIM’s other issued patents, further secures the Company’s control over the synthesis and use of the first-in-class drug, and provides patent protection for manufacturing until 2041.
The new patent significantly extends the potential development runway for the drug, securing AIM additional time to safely and confidently develop its drug program as it seeks U.S. Food and Drug Administration (“FDA”) approval for Ampligen in any of a series of indications. Ampligen has demonstrated broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM’s overall intellectual property portfolio covers the manufacture and use of Ampligen. AIM’s patents include Ampligen in the treatment of cancer (U.S. patent 11,813,279, expires August 9, 2039), the Post-COVID condition of fatigue (Netherlands’ patent 2032813, expires August 21, 2042) and endometriosis (U.S. patent 12,102,649, expires October 22, 2040).
AIM CEO Thomas K. Equels commented, “This patent is a significant milestone for AIM as it represents the final step in a multi-year project to strengthen and secure our global patent portfolio surrounding Ampligen. AIM now has extended patent protection for the manufacture of Ampligen, the composition of Ampligen and the way in which Ampligen can be utilized as a therapeutic for a diverse collection of unmet medical needs, from deadly cancers to Post-COVID conditions to endometriosis.”
Significantly, AIM’s intellectual property protection for Ampligen also includes multiple Orphan Drug Designations (“ODD”) from the FDA and the European Medicines Agency (“EMA”). FDA designation grants seven years of market exclusivity after commercial approval and EMA designation grants 10 years of market exclusivity after such approval. AIM’s orphan drug designations include Metastatic Melanoma (US), Renal Cell Carcinoma (US), Pancreatic Adenocarcinoma (US and EU), Ebola Virus Disease (US and EU), Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (US) and HIV (US).
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The granting of patents and Orphan Medicinal Production Designation, while beneficial, do not assure commercial approval. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does the newly granted patent No. 12312376 impact AIM ImmunoTech Inc.'s competitive position in the biopharmaceutical market, specifically regarding Ampligen's manufacturing processes?
What are the implications of AIM ImmunoTech Inc.'s extended patent protection until 2041 for Ampligen in terms of research, development, and potential market exclusivity after FDA approval?
Can you clarify how AIM ImmunoTech Inc. plans to leverage its multiple Orphan Drug Designations alongside the new patent to maximize Ampligen's potential in treating various unmet medical needs?
What strategies does AIM ImmunoTech Inc. have in place to address the risks and uncertainties associated with bringing Ampligen to market, considering the forward-looking statements in the recent press release?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
